MatsukiyoCocokara stock
3088.TJPXMatsukiyoCocokara & Co., HealthcareISIN JP3869010003
75Score 75 out of 100, Strong
Price and trend
84 / 100
Price history
−6.2% in one yearThe chart shows daily closes over 19 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 13% above it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 60).
The price is 6.4% below its 52-week high. Largest decline in 19 years: 52% (December 2007 to March 2011).
Chart figures for advanced users
- SMA 50$16.06
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$15.51
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)60
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$13.83
- The lowest closing price of the last twelve months.
- Resistance$18.73
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- MatsukiyoCocokara & Co. belongs to the Medical (Pharmaceuticals) industry (Japan) and, with a market value of $6.89B, is number 10 of 15 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $7B (up 5.3% year on year) and earnings of $349.26M (up 2%).
- For fiscal 2027, analysts expect on average revenue of $7.33B (up 4.7%) and adjusted earnings per share of $0.96 (up 8.5%).
Show more
- MEQIRI Score 75 out of 100 (Strong): rank 59 of 702 in Healthcare, median 53.
- The P/E is 19.2 (Medical (Pharmaceuticals) median 21.2, own median of recent years 17.8).
- Our model puts fair value at $22.51, with the price 24% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $635.41M, financial debt $99.8M.Stability 92
- Reliable dividendNo dividend cut for 15 years.Capital allocation 53
- Consistently profitableProfit in all 10 fiscal years from 2017 to 2026.Fundamentals 88
Weaknesses
- DilutionShare count up 29% since 2021.Capital allocation 53
Its standout strengths are stability and fundamentals.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 74 to 75.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Significantly undervaluedClosing price of 12 Nov 2026, used by the daily score.
In our model the price counts as cheap below $17.31 and expensive above $32.16 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $25.64 (cash-flow model) and $19.37 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 6.4%. At 7.4% the fair value would be $20.37, at 5.4% it would be $25.65.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.2).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 5.4% on the twelve months before. Revenue has grown solidly since 2007, at about 6% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 33%, operating 8%, net 5%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 13 Nov 2026today
- Last reported
- 10 Aug 2026EPS reported $0.24 (expected $0.22)above expectations
Analyst estimates
Earnings estimates have barely changed since 25 Oct 2026.
- Earnings per share
- $0.960.0%
- Revenue
- $7.33B0.0%
- Earnings per share
- $1.020.0%
- Revenue
- $7.56B−0.1%
MEQIRI has stored the estimates since 25 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at MatsukiyoCocokara
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 75
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Pharmaceuticals)
The next larger and next smaller companies by market value
- Kyowa Kirin4151.T $8.4B77
- Corcept TherapeuticsCORT $8.07B75
- Kiniksa Pharmaceuticals InternationalKNSA $7.56B68
- Tsuruha Holdings3391.T $7.1B62
- Abbott IndiaABBOTINDIA.NS $6.01B75
- LiquidiaLQDA $5.24B43
- Prestige Consumer HealthcarePBH $2.15B56
- CosmoCMHC.SW $1.21B37
ETFs that hold MatsukiyoCocokara
Held by 27 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares MSCI Japan Small Cap UCITS ETFIUS4 | 0.42% | 0.58% | €548.59M |
| JPM Global Equity Multi-Factor UCITS ETF USD AccJPGL | 0.13% | 0.19% | €282.02M |
| Amundi Prime Japan UCITS ETF DR (D)PR1J | 0.10% | 0.05% | €4.34B |
Show 5 more
| Amundi Japan TOPIX II UCITS ETF EUR DistLYY4 | 0.10% | 0.45% | €633.4M |
| L&G Japan Equity UCITS ETFETLR | 0.09% | 0.10% | €948.97M |
| iShares Core MSCI Japan IMI UCITS ETFEUNN | 0.09% | 0.12% | €7.17B |
| Vanguard FTSE Japan UCITS ETF EUR Hedged AccumulatingVJPE | 0.08% | 0.13% | €4.58B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.05% | 0.35% | €8.27B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 13 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ¥159.70)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 31 Oct 2026)
- Valuation signal Undervalued since 11 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.